Daniel S Karelitz

Daniel S. Karelitz

Partner
Daniel S. Karelitz
Boston
+1 617 570 8190

Dan Karelitz is a partner in the firm's Business Law department and a member of the Tax practice. Dan has strong general tax experience, advising sponsors on fund formation and portfolio company acquisition, disposition, and restructuring matters in the technology, private equity and real estate spaces. In addition, borrowing on deep experience in the private equity and real estate transaction space, and combined with his background as an organic chemist, Dan has a particular focus on the Life Sciences sector advising clients on structuring their operations, strategic transactions, acquisitions and divestitures in a tax-efficient manner.

He joined Goodwin in 2007.

Representative Matters

  • Fusion Pharmaceuticals in its $212.5 million initial public offering
  • Moderna in its $604 million initial public offering; $500 million follow-on offering; and $1.34 billion follow-on offering
  • Black Diamond Therapeutics in its $231.3 million initial public offering
  • Xeris Pharmaceuticals in its concurrent $89.3 million offering of common stock and convertible senior notes
  • Immatics, N.V. in its ~$1 billion business combination with ARYA Sciences Acquisition Corp. and listing on Nasdaq
  • BridgeBio Pharma in its $372.7 million initial public offering
  • Ascentage Pharma in its $61 million initial public offering on the HKSE
  • Avadel Pharmaceuticals in its $65 million financing transaction and its $125 million follow-on public offering
  • BeiGene in the sale of $2.8 billion of shares to Amgen
  • Orchard Therapeutics in its $225 million initial public offering
  • AquaVenture Holdings in its $117 million initial public offering
  • Intellia Therapeutics in its $108 million initial public offering
  • CRISPR Therapeutics in its $56 million initial public offering and its $200 million follow-on offering

  • Inseego Corp. in its offering of $100 million in convertible senior notes
  • Cerence, Inc. in its offering of $175 million in convertible senior notes
  • HubSpot, Inc. in its offering of $460 million in convertible senior notes
  • Health Catalyst in its offering of $200 million in convertible senior notes
  • Model N, Inc. in its offering of $150 million in convertible senior notes
  • Everbridge, Inc. in its offering of $450 million in convertible senior notes
  • Slack Technologies in its offering of $750 million in convertible senior notes
  • RingCentral in its offering of $1 billion in convertible senior notes
  • Zendesk in its offering of $1.15 billion in convertible senior notes
  • Otka in its offering of $1 billion in convertible senior notes
  • Varonis Systems in its offering of $220 million in convertible senior notes
  • 2U, Inc. in its offering of $380 million in convertible senior notes

  • Thrive Earlier Detection Corp. in its $110 million Series A financing and Galecto in its $40 million Series C financing
  • Cullinan Oncology in its $100 million Series B financing
  • ElevateBio in its $170 million Series B financing 
  • Moderna Therapeutics in its $110 million Series D financing and $500 million Series E financing
  • Intellia Therapeutics in its $15 million Series A financing and $70 million Series B financing
  • Nimbus Therapeutics in its $43 million Series B financing and $65 million Series C financing
  • Scholar Rock in its $36 million Series B financing and $47 million Series C financing
  • Cullinan Oncology in its $150 million Series A financing
  • Kymera Therapeutics in its $30 million Series A financing
  • Ginkgo Bioworks in its agreement with Bayer to launch JoynBio for $100 million Series A investment

  • Moderna in its strategic collaboration with Lonza Ltd.
  • Alnylam Pharmaceuticals in its $2 billion strategic collaboration with Blackstone; and in its development and commercialization collaboration with Dicerna Pharmaceuticals
  • Promedior, Inc in its ~$1 billion definitive merger agreement with Roche
  • Yantriks in its sale to Blue Yonder Group
  • AquaVenture in its $1.1 billion sale to Culligan
  • Backstone Life Sciences in its collaboration with Ferring Pharmaceuticals for $570 million
  • Semma Therapeutics in its $950 million sale to Vertex Pharmaceuticals
  • BlueRock Therapeutics in its $1 billion sale to Bayer AG
  • CRISPR Therapeutics in its strategic transaction with Bayer HealthCare to form Casebia Therapeutics; and subsequently in connection to the unwind of Casebia Therapeutics
  • Teva Pharmaceuticals in its $3.2 billion acquisition of Auspex Pharmaceuticals
  • Versant Ventures in its strategic transaction with Bayer to form BlueRock Therapeutics, with a combined financing amount of $225 million
  • Foundation Medicine in its strategic collaboration with Roche, valued at more than $1 billion, and subsequent $2.2 billion merger with Roche
  • Quartet Medicine in its $595 million strategic collaboration with Merck
  • Nimbus Therapeutics in its sale of Nimbus Apollo to Gilead, with $400 million upfront and the potential to receive an additional $800 million over time and strategic alliance with Celgene Corporation in immunology
  • CRISPR Therapeutics in its collaboration with Bayer, valued up to $335 million upfront
  • Padlock Therapeutics in its $225 million sale to Bristol Myers Squibb
  • F-star Alpha in its agreement with Bristol-Myers Squibb
  • Moderna Therapeutics in its collaboration with AstraZeneca to co-develop and co-commercialize immune-oncology mRNA Therapeutics 
  • Warp Drive Bio in its acquisition by Revolution Medicines
  • Sage Therapeutics in its collaboration with Shionogi for $90 million up front and potential deal value in excess of $575 million
  • Pairwise Plants in its collaboration with Monsanto to advance agriculture research and development by leveraging gene editing technology for $100 million
  • Alnylam Pharmaceuticals on its strategic restructuring of its RNAi therapeutics alliance with Sanofi

Areas of Practice

Credentials

Education

JD2008

Georgetown University

(magna cum laude, Order of the Coif)

MS2004

Emory University

BS2004

Emory University

(Phi Beta Kappa)

Admissions

Bars

  • Massachusetts

Recognition & Awards

Dan was listed as an Up and Coming Lawyer for Tax in Massachusetts by Chambers USA 2023. The Legal 500 2023 also recognized Dan for his work in US Taxes: non-contentious Nationwide.